# BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

> **NCT01263782** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Bevacizumab
- **DRUG:** Cixutumumab

## Key facts

- **NCT ID:** NCT01263782
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-17
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263782, "BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01263782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*